Founded in Eden Prairie, United States, Miromatrix Medical is a biotechnology company dedicated to eliminating the organ transplant waitlist. Their core mission is to develop fully biological human organs and organ-derived products using their patented perfusion decellularization/recellularization technology. Miromatrix focuses on creating bioengineered human organs to address the chronic shortage of transplantable organs, aiming to save lives and improve patient outcomes.
Notable affiliates include leading scientists and medical professionals in the field of organ transplantation and regenerative medicine. The company has garnered significant attention and investment from prominent venture capital firms and healthcare investors. Key achievements include successful preclinical trials demonstrating the potential of their technology to create functional human organs. Miromatrix's innovative approach has the potential to revolutionize organ transplantation, significantly impacting the lives of patients awaiting life-saving transplants.
